Our Story

Baiya Phytopharm’s plant-based technology is a cutting-edge solution that is quick, simple, and scalable, aiming to replace biotech’s fermenter with plants.

The platform has the flexibility to produce biopharmaceutical products of interest within weeks rather than months or years, resulting in a faster process and lower cost of research and development for products, such as cosmetic raw materials, diagnostic test kit materials, and therapeutics for cancer and infectious diseases. we have been scaling up our platform from scratch to hatch within our tiny laboratory since founded in 2018. Currently, we have a cGMP facility in Bangkok, Thailand to produce clinical materials of plant-produced protein and can produce up to 5 million doses of COVID-19 vaccine per month. 



Our champion is the COVID-19 vaccine, which is the first to be locally developed and manufactured in Thailand.

We have developed our first generation of plant-based COVID-19 vaccine, Baiya-SARS-CoV-2-Vax 1, which contains a recombinant RBD protein of SARS-CoV-2 virus. In July 2021, our vaccine was the first to test in human trials for plant-produced COVID-19 vaccine in Asia. With changes in the pandemic, the second candidate, Baiya-SARS-CoV-2-Vax 2, were developed and modeled after the prototype (Wuhan) SARS-CoV-2 RBD antigen. The preclinical study demonstrated a high protective efficacy and an improvement of the immune response against SARS-CoV-2 and its variants, compared to our first-generation vaccine. This First-in-Human (FIH) clinical trial of Baiya SARS-CoV-2-Vax 2 began in March 2022 and enrolled healthy adults aged 18 to 64 years to receive the vaccine at the assigned dosage. The trial’s independent Data Safety Monitoring Board (DSMB) has reviewed and recommended the trial to continue through the second cohort to collect additional data as the lead candidate induces promising immune responses.

Our team combines deep technological expertise in plant biotech, pharmaceutical production, and clinical development to create pharmaceutical candidates for highly unmet medical needs of the Asia-Pacific region. We have generated a broad proprietary portfolio of candidates, including monoclonal antibodies for cancer and infectious diseases and new vaccines for neglected tropical diseases.

We have achieved to be the first plant-based cGMP facility for human in Asia.

“Multi-product manufacturing facility”